How We Score
How we vet the research — transparency first
47
/100
38
/100
46
/100
Preliminary
Adaptive resistance in cancer immunotherapy.
46
/100
Preliminary
Neurobiology of exercise in Parkinson's disease.
38
/100
Preliminary
Promises of reprogramming-induced rejuvenation.
38
/100